The role of iron in patients after bone marrow transplantation

Blood Reviews

Volumn 22, Issue SUPPL. 2, 2008, Pages

  de Witte, Theo ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Haemopoietic stem cell transplantation; Iron chelation therapy; Iron overload; Iron related complications; Serum ferritin

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN;

BACTEREMIA; BETA THALASSEMIA; CHRONIC LIVER DISEASE; COLITIS; FERRITIN BLOOD LEVEL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; LIVER VENOOCCLUSIVE DISEASE; MYELODYSPLASTIC SYNDROME; PHLEBOTOMY; PNEUMONIA; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD;

EID: 57049153528     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(08)70005-5     Document Type: Review

References (52)

1. Gordon L.I., Brown S.G., Tallman M.S., et al. Sequential changes in serum iron and ferritin in patients undergoing high-dose chemotherapy and radiation with autologous bone marrow transplantation: possible implications for treatment related toxicity. Free Radic Biol Med 18 (1995) 383-389
2. Dürken M., Nielsen P., Knobel S., et al. Nontransferrin-bound iron in serum of patients receiving bone marrow transplants. Free Radic Biol Med 22 (1997) 1159-1163
3. Sahlstedt L., Ebeling F., von Bonsdorff L., et al. Nontransferrin-bound iron during allogeneic stem cell transplantation. Br J Haematol 113 (2001) 836-838
4. Dürken M., Herrnring C., Finckh B., et al. Impaired plasma antioxidant defense and increased nontransferrin-bound iron during high-dose chemotherapy and radiochemotherapy preceding bone marrow transplantation. Free Radic Biol Med 28 (2000) 887-894
5. Butt N.M., and Clark R.E. Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia. Bone Marrow Transplant 32 (2003) 909-913
6. Gaziev J., Sodani P., Polchi P., et al. Bone marrow transplantation in adults with thalassemia. Treatment and long-term follow-up. Ann NY Acad Sci 1054 (2005) 196-205
7. Malcovati L., Porta M.G., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 23 (2005) 7594-7603
8. Cappellini D.M., Tavazzi D., Duca L., Marelli S., and Fiorelli G. Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in beta-thalassemia intermedia. Transfus Sci 23 3 (2000 Dec) 245-246
9. Cortelezzi A., Cattaneo C., Cristiani S., et al. Nontransferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?. Hematol J 1 (2000) 153-158
10. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13 (2007) 1096-1101
11. Evens A.M., Mehta J., and Gordon L.I. Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 34 (2004) 561-571
12. Clemens M.R., Ladner C., Schmidt H., et al. Decreased essential antioxidants and increased lipid hydroperoxides following high-dose radiochemotherapy. Free Radic Biol Med 7 (1989) 227-232
13. Dürken M., Agbenu J., Finckh B., et al. Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation. Bone Marrow Transplant 15 (1995) 757-762
14. Hunnisett A., Davies S., McLaren-Howard J., et al. Lipoperoxides as an index of free radical activity in bone marrow transplant recipients. Preliminary observations. Biol Trace Elem Res 47 (1995) 125-132
15. Wayner D.D., Burton G.W., Ingold K.U., et al. The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim Biophys Acta 924 (1987) 408-419
16. Miceli M.H., Dong L., Grazziutti M.L., et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant 37 (2006) 857-864
17. Altes A., Remacha A.F., Sarda P., et al. Early clinical impact of iron overload in stem cell transplantation. A prospective study. Ann Hematol 86 (2007) 443-447
18. Altes A., Remacha A.F., Sarda P., et al. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant 34 (2004) 505-509
19. Schaible U.E., and Kaufmann S.H. Iron and microbial infection. Nat Rev Microbiol 2 (2004) 946-953
20. Blijlevens N.M., Donnelly J.P., and De Pauw B.E. Mucosal barrier injury: biology, pathology, clinical counterparts andcon-sequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 25 (2000) 1269-1278
21. Pullarkat V., Blanchard S., Tegtmeier B., et al. Iron overload adversely affects survival and increases risk of graft-versus-host disease and blood stream infections after allogeneic hematopoietic stem cell transplantation. Blood 110 (2007) abstract 2981.
22. Tomas J.F., Pinilla I., Garcia-Buey M.L., et al. Long-term liver dysfunction after allogeneic bone marrow transplantation: clinical features and course in 61 patients. Bone Marrow Transplant 26 (2000) 649-655
23. Iqbal M., Creger R.J., Fox R.M., et al. Laparoscopic liver biopsy to evaluate hepatic dysfunction in patients with hematologic malignancies: a useful tool to effect changes in management. Bone Marrow Transplant 17 (1996) 655-662
24. McKay P.J., Murphy J.A., Cameron S., et al. Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation. Bone Marrow Transplant 17 (1996) 63-66
25. Harrison P., Neilson J.R., Marwah S.S., et al. Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation. J Clin Pathol 49 (1996) 853-856
26. Angelucci E., Muretto P., Nicolucci A., et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 100 (2002) 17-21
27. Azar N., Valla D., Abdel-Samad I., et al. Liver dysfunction in allogeneic bone marrow transplantation recipients. Transplantation 62 (1996) 56-61
28. Lee J.L., Gooley T., Bensinger W., et al. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 5 (1999) 306-315
29. Litzow M.R., Pérez W.S., Klein J.P., et al. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol 119 (2002) 1115-1124
30. Morado M., Ojeda E., Garcia-Bustos J., et al. Serum ferritin as risk factor for veno-occlusive disease of the liver. Prospective cohort study. Hematology 2 (2000) 505-512
31. Kallianpur A.R., Hall L.D., Yadav M., et al. The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 35 (2005) 1155-1164
32. Clark J.G., Hansen J.A., Hertz M.I., et al. NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 147 (1993) 1601-1606
33. Fukuda T., Hackman R.C., Guthrie K.A., et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 102 (2003) 2777 2285
34. Kantrow S.P., Hackman R.C., Boeckh M., et al. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation 63 (1997) 1079-1086
35. Wong R., Rondon G., Saliba R.M., et al. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer. Bone Marrow Transplant 31 (2003) 1157-1163
36. Crawford S.W., and Hackman R.C. Clinical course of idiopathic pneumonia after bone marrow transplantation. Am Rev Respir Dis 147 (1993) 1393-1400
37. Balla J., Jacob H.S., Balla G., et al. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci USA 90 (1993) 9285-9289
38. Crouch E. Pathobiology of pulmonary fibrosis. Am J Physiol 259 (1990) L159-L184
39. Lucarelli G., and Gaziev J. Advances in the allogeneic transplantation for thalassemia. Blood Rev 22 (2008) 53-63
40. Lucarelli G., Galimberti M., Polchi P., et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 322 (1990) 417-421
41. Armand P., Kim H.T., Cutler C.S., et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109 (2007) 4586-4588
42. Altes A., Remacha A.F., Sureda A., et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 29 (2002) 987-989
43. Mahindra A., Bolwell B., Sobecks R., et al. Elevated pretransplant serum ferritin in autologus stem cell transplant. Blood 110 (2007) abstract 606.
44. Mahindra A., Bolwell B., Sobecks R., et al. Prognostic impact of elevated pretransplant serum ferritin in allogeneic hematopoietic stem cell transplantation. Blood 110 (2007) abstract 1109.
45. Mahindra A., Sobecks R., Rybicki L., et al. Elevated ferritiin is associated with poorer survival following nonablative allogeneic transplantation. Blood 110 (2007) abstract 1986.
46. Au W.Y., Lam W.M., Chu W.C., et al. A magnetic resonance imaging study of iron overload in haemopoietic stem cell transplant recipients with increased ferritin levels. Transplant Proc 39 (2007) 3369-3374
47. Takatoku M., Uchiyama T., Okamoto S., et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anaemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 78 (2007) 487-494
48. Leitch H.A. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res 31 Suppl 3 (2007) S7-S9
49. Rose C., Brechignac S., Vassilief D., et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 110 (2007) abstract 249.
50. Angelucci E., Muretto P., Lucarelli G., et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Blood 90 (1997) 994-998
51. Li C.K., Lai D.H., Shing M.M.K., et al. Early iron reduction programme for thalassaemia patients after bone marrow transplantation. Bone Marrow Transplant 25 (2000) 653-656
52. Strasser S.I., Kowdley K.V., Sale G.E., et al. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant 22 (1998) 167-173